Effects of estrogen on heart disease prevention

NewsGuard 100/100 Score

Researchers at Yale School of Medicine and seven other national institutions are recruiting patients to participate in the Kronos Early Estrogen Prevention Study (KEEPS) to look at the effects of estrogen on heart disease prevention.

The study will explore whether beginning hormone therapy in women during the menopausal transition (ages 42 to 58) protects against atherosclerosis, the major cause of heart attacks. Results from a prior study of older women called the Women's Health Initiative (WHI) estrogen plus progestin trial suggested there were few benefits of estrogen on atherosclerosis. The National Institutes of Health halted the study in 2002, but KEEPS will explore issues raised by WHI. Women in WHI were postmenopausal, with a mean age of 62.7, yet most women begin hormone treatment much younger, at the onset of menopausal symptoms.

"Once atherosclerosis is present, it is already too late to prevent it," said Yale principal investigator Hugh Taylor, M.D., associate professor in the Department of Obstetrics, Gynecology & Reproductive Sciences at Yale. "We think estrogen can help to prevent the disease if started early enough."

Prior to the WHI, most data suggested that hormone replacement therapy was associated with a high degree of protection (30 to 50 percent reductions) against coronary heart disease, mortality and osteoporotic fractures, in addition to a small increase in breast cancer risk.

The KEEPS trial is a randomized, double-blind trial of 720 women designed to provide prospective data on the risks and benefits of early menopausal hormone therapy (MHT). The Yale team is seeking 90 healthy, recently menopausal women ages 42 to 58 for the trial that will study the effects of using pill and skin patch hormone therapy.

Women interested in participating in the study may contact Diane Wall, clinical research nurse coordinator at 203-785-4739 or [email protected]. Local obstetrics & gynecology practitioners will also have information on study participation.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study: Empagliflozin shows mixed results in heart attack patients